CLASS II Drug recall · Reported 7 Oct 2020 · FDA Enforcement Report

Pharma Inc.Potassium Chloride Extended-Release Tablets recalled

Strides is recalling Strides Pharma Inc.Potassium Chloride Extended-Release Tablets, USP 8mEq (600 mg), distributed nationwide in the US. The recall was initiated on 24 Aug 2020 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codes7240675A; Exp. 12/31/2021
NDC64380-860, 64380-861
UPC0364380860068, 0364380861065
Quantity recalled11,280 bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0001-2021
FDA event ID
86283
Recalling firm
Strides, Lambertville, NJ
Manufacturer
Strides Pharma Science Limited
Classification
Class II
Status
Terminated
Recall initiated
24 Aug 2020
FDA classified
1 Oct 2020
Reported
7 Oct 2020
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Potency & Assay

Timeline

24 Aug 2020Recall initiated by company
1 Oct 2020Classified by FDA+38 days
7 Oct 2020Published in enforcement report+6 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Failed Dissolution Specifications

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

Strides Pharma Inc.Potassium Chloride Extended-Release Tablets, USP 8mEq (600 mg) 100 Tablets Rx Only Manufactured by: Strides Pharma Science Limited Bengaluru -562106 India Distributed by: Strides Pharma Inc., East Brunswick NJ 08816 NDC 64380-860-06

Where it was distributed

nationwide

Nationwide

Questions about this recall

Is Pharma Inc.Potassium Chloride Extended-Release Tablets, USP 8mEq (600 mg) recalled?

Yes. Strides recalled Pharma Inc.Potassium Chloride Extended-Release Tablets, USP 8mEq (600 mg) on 24 Aug 2020. The recall is Class II and its status is Terminated. Recall number D-0001-2021.

Why was it recalled?

Failed Dissolution Specifications

Which lots are affected?

7240675A; Exp. 12/31/2021

Where was it sold?

nationwide

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

Other Potassium Chloride recalls

All 21
ReportedClassRecallCompanyReasonWhere
DrugCLASS IPotassium Chloride Inj., 20 mEq total in Flexible Container recalledPotassium ChlorideOtsuka ICU MedicalOtherNationwide
DrugCLASS IPotassium Chloride Inj., 10 mEq total in Flexible Container recalledPotassium ChlorideOtsuka ICU MedicalOtherNationwide
DrugCLASS IPotassium Chloride Inj., 20 mEq total in flexible container recalledPotassium ChlorideICU MedicalLabeling ErrorsNationwide
DrugCLASS IPotassium Chloride Inj., 10 mEq total recalled by ICU MedicalPotassium ChlorideICU MedicalOtherNationwide
DrugCLASS IIPotassium Chloride Extended-Release Tablets, USP, 10 mEq recalledPotassium ChlorideThe Harvard Drug GroupPotency & AssayNationwide